Cisbio international expands its list of serine/threonine kinases validated using HTRF Kinease; company's universal kinase assay platform now validated on 104 kinases
Cisbio international, a developer of HTRF technology and services used in assay development and drug screening, has expanded the list of kinases validated using its universal HTRF Kinease platform to include 34 additional kinases.
Launched in March 2006, HTRF Kinease is a universal and sensitive assay for the screening of serine/threonine (Ser/Thr) kinases, major targets in drug discovery.
With these additions, Cisbio has now validated its assay platform on 104 Ser/Thr kinases.
HTRF Kinease, developed in collaboration with Upstate USA, is based on a combination of three biotinylated substrates, a single proprietary monoclonal antibody and Cisbio's patented HTRF technology, and can be used for kinase selectivity assays and high-throughput screening.
With the imminent addition of another peptide substrate, Cisbio will continue to develop this program with regular increments of validated kinases.
"The adoption of HTRF Kinease has been extraordinary since its launch," said Francois Degorce, head of HTRF marketing and business development at Cisbio.
"Clients have produced outstanding data using HTRF Kinease not only with Cisbio validated kinases, but also using serine/threonine kinases not previously assessed by Cisbio, attesting to the robustness of the reagents and HTRF technology.
"We strongly believe that our antibody-based kinase screening platform fulfills our customers' expectations in terms of assay reliability and sensitivity".
In addition to HTRF Kinease, Cisbio offers a comprehensive line of toolbox reagents and custom labeling and assay development services for the creation of highly specific Ser/Thr and tyrosine kinase assays, all based on its HTRF technology.
This offers customers the ability to use a single technology for both universal and specific kinase assays, saving valuable development time and cost, and reinforces the position which Cisbio's proprietary HTRF technology holds in high-throughput screening, specifically in the area of kinase activity.
